Tuesday, May 21, 2019
News
NEWS HOME
»
PRESS RELEASES

TA Associates Announces Partnership with Indira IVF
  SocialTwist Tell-a-Friend  
   


Date: 15-04-2019 11:41AM
Source: TA Associates
Category: Business/ Finance, Healthcare & Biotechnology, General, Banking & Financial Services, Financial Analyst & Investors, Medical Devices, Business Services
Location: Boston, United States & Udaipur, Rajasthan, India

Business Wire India

TA Associates, a leading global growth private equity firm, today announced that it has completed a significant minority investment in Indira IVF, a leading India-based infertility treatment provider. Financial terms of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190414005020/en/

Founded in 2014 by Dr. Ajay Murdia, Dr. Kshitiz Murdia, Nitiz Murdia, Ashish Lodha and Manish Khatri, Indira IVF is one of India’s largest network of in-vitro fertilization (“IVF”) centers. The company offers a wide variety of infertility treatments, including advanced IVF technology. Indira IVF currently operates 59 centers across 16 states in India and has completed nearly 27,000 IVF cycles in the last 12 months. Indira IVF has a staff of 1,800, including more than 150 IVF specialists and 100 embryologists.

“We are excited about the opportunity to partner with Indira IVF, a leader in IVF in India that aims to provide affordable, high-quality IVF services, while delivering best-in-class clinical outcomes,” said Naresh Patwari, a Director at TA Associates Advisory Private Limited. “IVF is a large and fast-growing opportunity in India that we believe has the ability to make a lasting positive impact on the lives of millions of people. We look forward to working with Dr. Ajay Murdia and the management team at Indira IVF to help them continue their growth efforts in India and in international markets, both organically and inorganically, and to help them offer additional adjacent clinical services.”

“We have built a strong relationship with the TA Associates team,” said Dr. Ajay Murdia, Founder and Chairman of Indira IVF. “TA has made many investments in healthcare services businesses, both in India and globally, and has a deep understanding of our industry. We believe that our partnership with TA will help Indira IVF enhance its mission of providing world-class IVF services at affordable rates with best-in-class clinical outcomes, while simultaneously maintaining our patient-first approach and sharp focus on clinical excellence. We welcome TA to Indira IVF, and look forward to a successful, long-term partnership.”

Research suggests that infertility affects 10-15% of married couples in India. Ernst & Young estimates that more than 25 million couples actively seeking children in 2015 were suffering from infertility-related issues. Industry estimates suggest that there are 150,000-250,000 IVF cycles being done annually in India, and Ernst & Young expects the industry to grow at nearly 20% annually.

“The infertility treatment space, in particular IVF, represents a large and growing market,” said Dhiraj Poddar, a Managing Director at TA Associates Advisory Private Limited. “We look forward to this partnership with Indira IVF and are thrilled to be supporting this seasoned, talented and passionate team of professionals to help Indira IVF enter into its next phase of growth.”

Naresh Patwari and Dhiraj Poddar will join the Board of Directors of Indira IVF as nominee directors of TA Associates Advisory Private Limited.

Pioneer Legal (previously with DSK Legal) provided legal counsel and KPMG served as financial advisor to TA Associates. Veritas Legal provided legal counsel to Indira IVF. TA Associates Advisory Private Limited provided advisory services on the investment.

About Indira IVF
Indira IVF is a leading fertility hospital in India with 59 centers across 16 states. The company has more than 150 IVF specialists and 100 embryologists, and a total staff of more than 1,800 incorporating international treatment standards for infertility and assisted reproductive technologies such as IUI, IVF/ICSI, PGT and other technologies. Indira IVF is dedicated to providing its patients with the best medical treatment and care to fulfill their parenthood dreams, and more than 45,000 successful IVF cycles have been completed at Indira IVF. The company’s IVF treatments and services are delivered in an ethical, professional and caring environment by a team of IVF specialists, sonologists, embryologists, nurses, counselors and others who are leaders in their fields. In addition to the treatment of infertility, Indira IVF is actively engaged in spreading infertility awareness and has completed more than 1,800 free consultation camps in over 700 cities covering 20 states across India. Indira IVF has a world-class training center where doctors from India and abroad receive state-of-the-art training in the field of Assisted Reproductive Technology. For more information, please visit www.indiraivf.com.

About TA Associates
TA Associates is one of the most experienced global growth private equity firms. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $24 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com.


MULTIMEDIA AVAILABLE :
https://www.businesswire.com/news/home/20190414005020/en/


CONTACTS :

Marcia O’Carroll
TA Associates
617-574-6796
mocarroll@ta.com

Zachary Tramonti
BackBay Communications
617-391-0797
zachary.tramonti@backbaycommunications.com

More Press Releases

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1

Herbalife Nutrition Celebrates 20 Years of Success in India With the Unveiling of H24

GIA India Organised a GemKids Programme in New Delhi

NRI FT India and Digital Asset to Deliver DAML Driven Applications to Capital Markets

Analogix Introduces Its VirtualLink™ Reference Design for High-Performance Gaming Notebooks

Gupta Agarwal Foundation Donates $5 Million to Fund Heart Health Research and Education

CNIM to Optimize Renewable Heat Production for Nantes District Heating

Rubicon Capital Advisors Strengthens its Global Presence through the Formation of a Dedicated Investor Coverage Group and the Opening of a New Office in Seoul, South Korea

smartwater, the Perfect Accomplice for Original Thinkers!

Saurav Ganguly Joins My11Circle

Lattice’s New MachX03D FPGA Enhances Security with Hardware Root-of-Trust Capabilities

Lattice sensAI Delivers 10X Performance Boost for Low Power, Smart IoT Devices at the Edge

GLIDE and eBay Present the 20th Annual Auction for Power Lunch with Warren Buffett, May 26 – May 31

PEI-Genesis Promotes Peter Austin to General Manager North America and Corporate Senior Vice President

Onward Technologies Delivers PAT Growth of 50.9 Percent in FY 18-19, Board Recommends Final Dividend at 15 Percent

ams, Ibeo and ZF Partner to Deliver Industry-First Solid-State LiDAR Systems for the Automotive Industry

ICCPL, India’s Top Public Relation Agency Posts a Robust 100 Percent Growth in FY 18-19

New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery

Karisma Kapoor Gives Away AQE Awards 2019 New Delhi by Xel Research

Opening up GIFT City Bourses to Foreign Retail Investors, NRIs a Positive Step, Dr. Niranjan Hiranandani - CMD - Hiranandani Communities

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Rahul, Priyanka worked hard, Congress wi...
Will always be my hero says Priyanka on ...
This Chennai polyglot reads, writes over...
BJP demands probe into Delhi police offi...
Man wanted in robbery, murder case, held...
Ayodhya's Shri Sita Ram temple hosts Ift...
More...    
 
 Top Stories
White House tells former lawyer not... 
With terror on agenda, Swaraj depar... 
Jet Airways employees stage protest... 
Mau: Police disperses crowd gathere... 
Modi congratulates Joko Widodo on r... 
Ahead of opposition meet, Kumaraswa... 
Italy's head coach Roberto Mancini ... 
Women with sleep apnoea more likely...